Benefits are subject to the following:

- ✓ Pre-authorisation
- ✓ Bestmed guidelines
- ✓ Bestmed protocols
  - ➢ Below medicines are first line treatment. Second line medicines not listed, would be considered if clinical funding criteria is met as per protocol – without penalties.
- ✓ MediKredit Reference Price (MMAP)
  This is a reference pricing model applicable to all medicines with generic equivalents or biosimilars. MMAP sets the maximum reimbursable price for a list of generically similar or biosimilar products with a cost lower than that of the original medicine. This means that if you opt to use a medicine that is more expensive than the MMAP, you will have to pay the difference between the price of the chosen medicine and that of MMAP.

- This formulary is effective from 1 January 2026.
- This formulary is subject to change without notice.
- Available on all Bestmed options.

HYPOPHYSEAL ADENOMA

ACTIVE INGREDIENT	ALL OPTIONS
B	
BROMOCRIPTINE 2.5MG	YES